Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECT OF ERYTHROPOIETIN ON THE CLINICAL COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH ANEMIA: RESULTS OF NOT COMPARATIVE STUDY

https://doi.org/10.20996/1819-6446-2011-7-5-605-608

Full Text:

Abstract

Aim. To study the clinical efficacy of corrective therapy of anemia in patients with chronic heart failure (CHF) and ischemic heart disease (IHD). Material and methods. Patients (n=58; 32 female, 26 male; aged 47-85 years) with IHD and CHF with left ventricular ejection fraction (LVEF) <45% were included into the study. They received basic CHF therapy. Patients (n=12) with iron deficiency anemia also received erythropoietin and iron containing drugs during 12 weeks. Clinic and instrumental examination was performed before and after the treatment. Exercise tolerance was evaluated by 6-minute walk test. Results. The anemia was revealed in 14 (24.8%) patients, including 12 patients with iron deficiency anemia. By the end of 12 week therapy with erythropoietin and iron containing drugs significant increase (+36%) in 6-minute walk distance and LVEF (+32.5%), improvement of CHF NYHA functional class were observed. Besides increase in hemoglobin (+12.5%; p<0.001) and hematocrit (+5.8%; p<0.001) levels, as well as increase in red blood cells number (+8%; p<0.001) were found. Conclusion. In patients with CHF and IHD correction of anemia with erythropoietin and iron containing drugs additionally to the basic CHF/IHD therapy leads to a significant clinical and functional improvement.

About the Authors

V. M. Provotorov
Voronezh State Medical Academy named after N.N. Burdenko
Russian Federation


S. A. Avdeeva
Lipetsk Outpatient Clinic № 4
Russian Federation


References

1. Silverberg D.S., Wexler D., Sheps D. et al. The effect of correction of mild anemia in severe, resistant congestiv heart failure using subcutaneous erytropoietin and intravenous iron. A randomized controlled study. J Am Coll Cardiol 2001; 37: 1775 – 1780.

2. Tereshchenko S.N., Atroshchenko E.S., Uskach T.M. et al. Anemia as complication of chronic heart failure: prevalence, treatment, prognosis. Ter Arkh 2008;80(9):90-5. Russian (Терещенко С.Н., Атрощенко Е.С., Ускач Т.М. и др. Анемия как осложнение хронической сердечной недостаточности: распространенность, прогноз и лечение. Терапевтический архив 2008;9:90-95).

3. Chernov V.M., ed. Anemia is a hidden epidemic. M.: MegaPro; 2004. Russian (Чернов В.М., редактор. Анемия - скрытая эпидемия. М.: МегаПро; 2004).

4. Arutjunov G.P. Anemia in patients with chronic heart failure. Serdechnaja Nedostatochnost' 2003; 4 (5):224-228. Russian (Арутюнов Г.П. Анемия у больных хронической сердечной недостаточностью. Сердечная Недостаточность 2003; 4 (5):224-228).

5. Tereshchenko S.N., Dzhainani N.A., Uskach T.M., Kochetov A.G. Anemia and chronic heart failure. Kardiologija 2004;44(7):73-6. Russian (Терещенко С.Н., Джаинани Н.А., Ускач Т.М., Кочетов А.Г. Анемия и хроническая сердечная недостаточность. Кардиология 2004;44(7):73-6).

6. Shilov A.M., Mel'nik M.V., Sarycheva A.A. Anemia in heart failure. Russkij medicinskij zhurnal 2003; 11(9): 545-548. Russian (Шилов А.М., Мельник М.В., Сарычева А.А. Ане-мия при сердечной недостаточности. Русский медицинский журнал 2003; 11(9): 545-548).

7. Silverberg D.S., Iaina A., Wexler D. et al. The pathological consequences of anaemia. Clin Lab Haematology 2001; 23(1): 1-6.

8. Steinborn W., Doehner W., Anker S.D. Anemia in chronic heart failure – frequency and prognostic impact. Clin Nephrology 2003; 60 (Suppl 1): 103-107.

9. Singh A.K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.

10. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40: 27-33.

11. Guyatt G.H. Measurement of health-related quality of life in heart failure. J Am Coll Car-diol 1993; 22(4 Suppl A): 185A-191A.

12. Devereux R., Reichek N. Echocardargraphic assesment of left ventricular mass in man. Circulation 1977; 55: 613-618.

13. Silverberg D.S., Wexler D., Blum M. et al. The use subcutaneous erytropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestiv heart failure improves cardiac and renal function, functional cardiac class, and makedly reduces hospitalization. J Am Coll Cardiol 2000; 35: 1737 – 1744.

14. Wisniackl N., Aimson P., Lyle M. Is anemia a cause of heart failure in the elderly? Heart 2001; 85 suppl I: 4.


For citation:


Provotorov V.M., Avdeeva S.A. EFFECT OF ERYTHROPOIETIN ON THE CLINICAL COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH ANEMIA: RESULTS OF NOT COMPARATIVE STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(5):605-608. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-5-605-608

Views: 273


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)